News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,010 Results
Type
Article (40014)
Company Profile (288)
Press Release (664708)
Multimedia
Podcasts (47)
Webinars (12)
Section
Business (206505)
Career Advice (2020)
Deals (35733)
Drug Delivery (95)
Drug Development (82102)
Employer Resources (174)
FDA (16212)
Job Trends (14986)
News (348966)
Policy (32727)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (8)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (6)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (6)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (7)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2561)
Accelerated approval (5)
Adcomms (20)
Allergies (83)
Alliances (50056)
ALS (88)
Alzheimer's disease (1374)
Antibody-drug conjugate (ADC) (112)
Approvals (16217)
Artificial intelligence (242)
Autoimmune disease (20)
Automation (15)
Bankruptcy (360)
Best Places to Work (11738)
BIOSECURE Act (18)
Biosimilars (105)
Biotechnology (205)
Bladder cancer (61)
Brain cancer (27)
Breast cancer (265)
Cancer (2094)
Cardiovascular disease (171)
Career advice (1684)
Career pathing (29)
CAR-T (143)
Cell therapy (405)
Cervical cancer (19)
Clinical research (66714)
Collaboration (804)
Compensation (515)
Complete response letters (19)
COVID-19 (2593)
CRISPR (37)
C-suite (228)
Cystic fibrosis (101)
Data (2062)
Decentralized trials (2)
Denatured (17)
Depression (41)
Diabetes (256)
Diagnostics (6359)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (118)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (91)
Earnings (87269)
Editorial (36)
Employer branding (22)
Employer resources (148)
Events (114014)
Executive appointments (701)
FDA (17399)
Featured Employer (51)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (720)
Gene editing (100)
Generative AI (19)
Gene therapy (285)
GLP-1 (706)
Government (4421)
Grass and pollen (5)
Guidances (51)
Healthcare (18859)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (109)
Indications (27)
Infectious disease (2733)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (92)
Interviews (315)
IPO (16680)
IRA (40)
Job creations (3675)
Job search strategy (1431)
Kidney cancer (9)
Labor market (36)
Layoffs (464)
Leadership (16)
Legal (7932)
Liver cancer (72)
Lung cancer (302)
Lymphoma (139)
Machine learning (5)
Management (58)
Manufacturing (283)
MASH (63)
Medical device (13355)
Medtech (13360)
Mergers & acquisitions (19573)
Metabolic disorders (658)
Multiple sclerosis (77)
NASH (16)
Neurodegenerative disease (84)
Neuropsychiatric disorders (24)
Neuroscience (1887)
NextGen: Class of 2025 (6538)
Non-profit (4490)
Northern California (2539)
Now hiring (38)
Obesity (354)
Opinion (203)
Ovarian cancer (73)
Pain (80)
Pancreatic cancer (80)
Parkinson's disease (147)
Partnered (21)
Patents (224)
Patient recruitment (100)
Peanut (46)
People (57892)
Pharmaceutical (74)
Pharmacy benefit managers (18)
Phase I (20809)
Phase II (29423)
Phase III (21812)
Pipeline (1115)
Policy (130)
Postmarket research (2569)
Preclinical (8807)
Press Release (64)
Prostate cancer (98)
Psychedelics (30)
Radiopharmaceuticals (252)
Rare diseases (372)
Real estate (5995)
Recruiting (66)
Regulatory (22371)
Reports (46)
Research institute (2332)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (67)
Series A (124)
Series B (81)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2186)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3618)
State (2)
Stomach cancer (13)
Supply chain (65)
Tariffs (24)
The Weekly (28)
United States (22213)
Vaccines (674)
Venture capitalists (38)
Weight loss (230)
Women's health (34)
Worklife (15)
Date
Last 7 days (476)
Last 30 days (2167)
Last 365 days (33100)
2025 (9291)
2024 (35564)
2023 (40473)
2022 (51632)
2021 (56244)
2020 (54470)
2019 (46898)
2018 (35313)
2017 (32507)
2016 (31948)
2015 (38018)
2014 (31842)
2013 (26766)
2012 (28940)
2011 (29608)
2010 (27666)
Location
Africa (728)
Alabama (57)
Alaska (7)
Arizona (231)
Arkansas (14)
Asia (38696)
Australia (6288)
California (5802)
Canada (1945)
China (502)
Colorado (257)
Connecticut (264)
Delaware (135)
Europe (83793)
Florida (871)
Georgia (202)
Idaho (57)
Illinois (516)
India (25)
Indiana (301)
Iowa (9)
Japan (150)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (865)
Massachusetts (4385)
Michigan (215)
Minnesota (380)
Mississippi (2)
Missouri (78)
Montana (27)
Nebraska (25)
Nevada (60)
New Hampshire (62)
New Jersey (1678)
New Mexico (29)
New York (1660)
North Carolina (986)
North Dakota (7)
Northern California (2539)
Ohio (194)
Oklahoma (14)
Oregon (34)
Pennsylvania (1308)
Puerto Rico (12)
Rhode Island (30)
South America (1109)
South Carolina (20)
South Dakota (1)
Southern California (2186)
Tennessee (99)
Texas (867)
Utah (171)
Virginia (138)
Washington D.C. (60)
Washington State (538)
West Virginia (3)
Wisconsin (51)
705,010 Results for "eiger biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals
Sentynl Therapeutics, Inc. (Sentynl) and Eiger BioPharmaceuticals, Inc. (OTC: EIGRQ), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced the closing of the sale of Eiger’s Zokinvy® (lonafarnib) program to Sentynl.
May 3, 2024
·
11 min read
Deals
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas.
April 1, 2024
·
3 min read
Deals
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
Eiger BioPharmaceuticals, Inc. today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30.
January 4, 2024
·
5 min read
Mergers & Acquisitions
Amylyx Pivots to GLP-1 Space, Acquires Phase III-Ready Asset from Eiger
After pulling its ALS drug Relyvrio from the market, Amylyx Pharmaceuticals is looking to target the GLP-1 space with the purchase of Eiger BioPharmaceuticals’ avexitide, which has been studied for the treatment of hyperinsulinemic hypoglycemia.
July 10, 2024
·
2 min read
·
Tyler Patchen
Business
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the third quarter 2023 and provided a business update.
November 9, 2023
·
8 min read
Deals
Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year
Following a series of rejections and clinical failures, Eiger BioPharmaceuticals has declared bankruptcy and will sell all its assets as the company winds down operations.
April 2, 2024
·
2 min read
·
Tristan Manalac
Business
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today reported financial results for the second quarter 2023 and provided a business update.
August 14, 2023
·
8 min read
Biotech Bay
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 7:00 AM ET in New York, NY.
September 5, 2023
·
1 min read
Biotech Bay
Eiger BioPharmaceuticals to Host Business Update Call Tomorrow
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced that following an extensive portfolio prioritization exercise, the company will host a conference call and live webcast on Thursday, June 29, at 8:30 am ET.
June 28, 2023
·
1 min read
Business
Eiger BioPharmaceuticals Strengthens Management Team with New Appointments
Eiger BioPharmaceuticals, Inc. today announced the appointments of William G. Kachioff as Chief Financial Officer, and James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary.
April 13, 2023
·
5 min read
1 of 70,501
Next
